What is Cellectis?
Founded in 1999 and headquartered in Paris, France, Cellectis is a biopharmaceutical company dedicated to pioneering innovative pharmaceutical products and therapies. As a publicly traded entity since 2019, Cellectis operates across Europe and North America, focusing on the manufacturing of pharmaceuticals. The company strategically engages with both B2B and B2C markets, integrating mobile applications into its technological framework to enhance its market reach and operational efficiency. Its specialization lies in developing cutting-edge treatments, positioning it as a key player in the biopharmaceutical landscape.
How much funding has Cellectis raised?
Cellectis has raised a total of $521.5M across 5 funding rounds:
Corporate Investment
$22.2M
Stock Offering
$129M
Stock Offering
$163.7M
Other Financing Round
$164M
Debt
$42.6M
Corporate Investment (2014): $22.2M with participation from Merlin Nexus, Ridgeback Capital, OrbiMed, venBio, and Aquilo Capital Management
Stock Issuance/Offering (2015): $129M led by Undisclosed
Stock Issuance/Offering (2018): $163.7M supported by Goldman Sachs & Co, Barclays, and Citigroup
Other Financing Round (2018): $164M featuring Undisclosed
Debt (2022): $42.6M backed by European Investment Bank
Key Investors in Cellectis
European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution.
Barclays
Barclays PLC is a British multinational universal bank headquartered in London, providing a wide range of financial services to consumers, businesses, and institutions globally. The company operates through multiple divisions including retail banking, corporate and investment banking, wealth management, and credit cards.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services.
What's next for Cellectis?
The recent major strategic investment into Cellectis signals a pivotal phase for the company, likely aimed at accelerating the development and commercialization of its therapeutic pipeline. This substantial capital infusion, part of the $521.5M in total financing, suggests a focus on scaling operations, expanding clinical trials, and potentially forging new strategic partnerships. Given the enterprise-level nature of its funding, Cellectis is poised for significant expansion, potentially moving towards late-stage clinical development or preparing for broader market entry. The company's commitment to innovation in pharmaceutical manufacturing and its established presence across key markets indicate a strategic trajectory towards solidifying its position as a leader in the biopharmaceutical industry.
See full Cellectis company page
